Blue Sky Investments

Blue Sky Alternative Investments was a prominent Australian alternative asset manager that played a significant role in the life sciences sector through its venture capital arm, Blue Sky Venture Capital. The firm gained international attention in the biotech community for its successful investment in Hatchtech, which resulted in a major commercialization deal for a novel head lice treatment. However, the company faced severe financial distress following a critical report by a short-seller in 2018, leading to its eventual collapse and voluntary administration in 2019. During its peak, it was a key financier for early-stage Australian healthcare and biotechnology innovations, managing a dedicated Life Science Fund.